Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: Protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded, parallel intervention study

BMJ Open

Volumn 3, Issue 4, 2013, Pages

  Idorn, Thomas ^a   Knop, Filip K ^a   Jørgensen, Morten ^a   Jensen, Tonny ^a   Resuli, Marsela ^b   Hansen, Pernille M ^b   Christensen, Karl B ^a   Holst, Jens J ^a   Hornum, Mads ^a   Feldt Rasmussen, Bo ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b HILLERØD HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; GLUCOSE; LIRAGLUTIDE; LIXISENATIDE; PLACEBO;

ARTICLE; CARDIOVASCULAR FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG SAFETY; GLOMERULUS FILTRATION; GLYCEMIC CONTROL; HUMAN; KIDNEY FAILURE; LABORATORY TEST; LIFE EXPECTANCY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PANCREAS ISLET BETA CELL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; VON WILLEBRAND DISEASE;

EID: 84877727819     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2013-002764     Document Type: Article

References (38)

1. U S Renal Data System, USRDS 2011 Annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2011.
2. The Danish Society of Nephrology, Annual Data Report 2011.
3. Abe M, Okada K, Soma M. Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice. Curr Drug Metab 2011;12:57-69.
4. Rocco MV, Berns JS. KDOQI clinical practice guideline for diabetes and CKD: 2012 Update. Am J Kidney Dis 2012;60:850-86.
5. Graefe-Mody U, Friedrich C, Port A, et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin(*). Diabetes Obes Metab 2011;13:939-46.
6. Boulton DW, Li L, Frevert EU, et al. Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin. Clin Pharmacokinet 2011;50:253-65.
7. Arjona Ferreira JC, Corry D, Mogensen CE, et al. Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trial. Am J Kidney Dis 2013;61:579-81.
8. Kothny W, Shao Q, Groop PH, et al. One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment. Diabetes Obes Metab 2012;14:1032-9.
9. Sorensen VR, Mathiesen ER, Heaf J, et al. Improved survival rate in patients with diabetes and end-stage renal disease in Denmark. Diabetologia 2007;50:922-9. (Pubitemid 46559250)
10. London GM. Cardiovascular disease in chronic renal failure: pathophysiologic aspects. Semin Dial 2003;16:85-94. (Pubitemid 37356820)
11. Fellstrom BC, Jardine AG, Schmieder RE, et al . Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009;360:1395-407.
12. Heerspink HJ, Ninomiya T, Zoungas S, et al. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet 2009;373:1009-15.
13. Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005;353:238-48. (Pubitemid 41058323)
14. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011;377:2181-92.
15. Hayashino Y, Fukuhara S, Akiba T, et al. Diabetes, glycaemic control and mortality risk in patients on haemodialysis: the Japan dialysis outcomes and practice pattern study. Diabetologia 2007;50:1170-7. (Pubitemid 46701557)
16. Oomichi T, Emoto M, Tabata T, et al. Impact of glycemic control on survival of diabetic patients on chronic regular hemodialysis: a 7-year observational study. Diabetes Care 2006;29:1496-500. (Pubitemid 44127570)
17. Yoo DE, Park JT, Oh HJ, et al. Good glycemic control is associated with better survival in diabetic patients on peritoneal dialysis: a prospective observational study. PLoS ONE 2012;7:e30072.
18. Sisson EM. Liraglutide: clinical pharmacology and considerations for therapy. Pharmacotherapy 2011;31:896-911.
19. Bode B. Liraglutide: a review of the first once-daily GLP-1 receptor agonist. Am J Manag Care 2011;17:S59-70.
20. Neumiller JJ, Campbell RK. Liraglutide: a once-daily incretin mimetic for the treatment of type 2 diabetes mellitus. Ann Pharmacother 2009;43:1433-44.
21. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374:39-47.
22. Klonoff DC, Buse JB, Nielsen LL, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008;24:275-86. (Pubitemid 351160260)
23. European Medicines Agency. Summary of opinion (initial authorisation). http://www.ema.europa.eu/docs/en-GB/document-library/Summary-of-opinion--- Initial-authorisation/human/002445/WC500134872.pdf (accessed 8 Feb 2013).
24. European Medicines Agency. Annex I, Summary of product characteristics. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---ProductInformation/ human/000698/WC500051845.pdf (accessed 8 Feb 2013).
25. European Medicines Agency. Annex I, Summary of product characteristics. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/ human/001026/WC500050017.pdf (accessed 30 Aug 2012).
26. Linnebjerg H, Kothare PA, Park S, et al. Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol 2007;64:317-27. (Pubitemid 47283860)
27. Liu Y-H, Ruus P. Pharmacokinetics and safety of the GLP-1 agonist AVE0010 in patients with renal impairment (Abstract). Diabetes 2009;59(Suppl 1):A149-50.
28. Christensen M, Knop FK, Vilsboll T, et al. Lixisenatide for type 2 diabetes mellitus. Expert Opin Investig Drugs 2011;20:549-57.
29. Neumiller JJ. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. J Am Pharm Assoc (2003) 2009;49(Suppl 1):S16-29.
30. Agerso H, Jensen LB, Elbrond B, et al. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 2002;45:195-202. (Pubitemid 34208381)
31. Malm-Erjefalt M, Bjornsdottir I, Vanggaard J, et al. Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Drug Metab Dispos 2010;38:1944-53.
32. Davidson JA, Brett J, Falahati A, et al. Mild renal impairment and the efficacy and safety of liraglutide. Endocr Pract 2011;17:345-55.
33. Jacobsen LV, Hindsberger C, Robson R, et al. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide. Br J Clin Pharmacol 2009;68:898-905.
34. U.S. Food and Drug Administration. http://www.accessdata.fda.gov/ drugsatfda-docs/label/2010/022341lbl.pdf (accessed 30 Aug 2012).
35. Chatterjee DJ, Khutoryansky N, Zdravkovic M, et al. Absence of QTc prolongation in a thorough QT study with subcutaneous liraglutide, a once-daily human GLP-1 analog for treatment of type 2 diabetes. J Clin Pharmacol 2009;49:1353-62.
36. Morrow L, Hompesch M, Guthrie H, et al. Co-administration of liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interaction. Diabetes Obes Metab 2011;13:75-80.
37. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c332.
38. Riveline JP, Teynie J, Belmouaz S, et al. Glycaemic control in type 2 diabetic patients on chronic haemodialysis: use of a continuous glucose monitoring system. Nephrol Dial Transplant 2009;24:2866-71.